Holen Sie sich die Stockscreener-App
33.87
0.36%
0.12
Handel nachbörslich:
33.97
0.10
+0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.75
Offen:
$33.73
24-Stunden-Volumen:
1.84M
Relative Volume:
0.77
Marktkapitalisierung:
$5.63B
Einnahmen:
$1.48B
Nettoeinkommen (Verlust:
$241.66M
KGV:
23.64
EPS:
1.4325
Netto-Cashflow:
$480.33M
1W Leistung:
+2.57%
1M Leistung:
+22.01%
6M Leistung:
+6.04%
1J Leistung:
+22.98%
1-Tages-Spanne:
$33.63
$34.23
1-Wochen-Bereich:
$32.76
$35.52
52-Wochen-Spanne:
$25.16
$36.48
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
33.87 | 5.55B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com
Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com India
Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan
Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st
Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF S - GuruFocus
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF Score: 79/100 - GuruFocus
Will Alkermes plc benefit from government policyEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
B of A Securities Raises Price Target for ALKS to $36 | ALKS Sto - GuruFocus
Market Fear: Is Alkermes plc stock showing strong momentum2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How (ALKS) Movements Inform Risk Allocation Models - Stock Traders Daily
Alkermes PLC (ALKS) Stock Price Down 4.08% on Apr 7 - GuruFocus
RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating - marketscreener.com
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $70,315.38 in Stock - MarketBeat
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares in 10b5-1 trade - Stock Titan
Alkermes (NASDAQ: ALKS) 2026 proxy outlines CEO change, $1.48B 2025 revenue and Avadel acquisition - Stock Titan
Alkermes plc (NASDAQ: ALKS) Form 144 lists affiliate sale amounts - Stock Titan
Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet? - simplywall.st
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program - CSRwire
Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - Sleep Review
Alkermes plc (ALKS) stock price, news, quote and history - Yahoo Finance UK
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com South Africa
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Top 2 Health Care Stocks That May Implode In April - Sahm
Alkermes launches phase 3 trials for narcolepsy drug alixorexton By Investing.com - Investing.com Australia
Alkermes (ALKS) CMO sells 9K shares after option exercise - Stock Titan
Alkermes (ALKS) insider sells multiple blocks of shares, Form 144 shows dates and proceeds - Stock Titan
Alkermes (ALKS) Advances Alixorexton into Phase 3 Trials for Nar - GuruFocus
Alkermes (NASDAQ:ALKS) Sets New 1-Year HighStill a Buy? - MarketBeat
Alkermes stock hits 52-week high at $36.46 - Investing.com
Lilly’s $7.8 Billion Bet Takes It Beyond Obesity Into Sleep - Bloomberg.com
Alkermes launches phase 3 trials for narcolepsy drug alixorexton - Investing.com
FinancialContentAlkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 - FinancialContent
Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest - Insider Monkey
10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - Insider Monkey
Highs Report: What is the target price for Alkermes plc stockEntry Point & Technical Pattern Based Signals - baoquankhu1.vn
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy - BioWorld MedTech
Alkermes Shares Surge 15% Following Lilly-Centessa Deal - Intellectia AI
Alkermes’ Future: Critical Developments and Financial Outlook - timothysykes.com
Alkermes (ALKS) Shares Surge by Nearly 18% in Market Rally - GuruFocus
Alkermes PLC (ALKS) Shares Up 18.16% on Mar 31 - GuruFocus
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):